Human Immunoglobulin E specific for Carya laciniosa pollen allergens (sIgE (Carya laciniosa))

Human Immunoglobulin E (IgE) antibodies specific for Carya laciniosa (Shellbark Hickory) pollen allergens are the primary mediators of allergic sensitization and clinical symptoms in individuals allergic to this tree species (Source: AAAAI). These antibodies are produced by B cells upon exposure to hickory pollen and subsequently bind to high-affinity FcεRI receptors on mast cells and basophils (Source: NIH/StatPearls). When the individual is re-exposed to Carya laciniosa pollen, the allergens cross-link the receptor-bound IgE, triggering the immediate release of histamine, proteases, and cytokines (Source: PubMed). This physiological response results in the symptoms of hay fever, such as sneezing, rhinorrhea, and itchy eyes, and can contribute to the pathogenesis of allergic asthma. Therapeutic interventions like Omalizumab target the circulating IgE pool to prevent this binding, effectively dampening the allergic inflammatory cascade (Source: FDA/Omalizumab Prescribing Information).

Other names

Shellbark hickory pollen-specific IgEAnti-Carya laciniosa IgEHickory pollen-specific IgEIgE specific for Shellbark Hickory

Anti-IgE monoclonal antibodies bind to the Cε3 domain of the Fc region of circulating IgE. This binding prevents IgE from interacting with the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils, thereby inhibiting the release of inflammatory mediators that cause allergic symptoms (Source: PubMed, PMID: 24565708).